Hepion Pharmaceuticals (HEPA) Stock Forecast, Price Target & Predictions
HEPA Stock Forecast
Hepion Pharmaceuticals stock forecast is as follows: an average price target of $70.00 (represents a 9982.10% upside from HEPA’s last price of $0.69) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
HEPA Price Target
The average price target for Hepion Pharmaceuticals (HEPA) is $70.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $70.00. This represents a potential 9982.10% upside from HEPA's last price of $0.69.
HEPA Analyst Ratings
According to 1 Wall Street analysts, Hepion Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for HEPA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Hepion Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 01, 2022 | Kristen Kluska | Cantor Fitzgerald | $70.00 | $24.60 | 184.55% | 9982.10% |
The latest Hepion Pharmaceuticals stock forecast, released on Mar 01, 2022 by Kristen Kluska from Cantor Fitzgerald, set a price target of $70.00, which represents a 184.55% increase from the stock price at the time of the forecast ($24.60), and a 9982.10% increase from HEPA last price ($0.69).
Hepion Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.69 | $0.69 | $0.69 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Hepion Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Hepion Pharmaceuticals's last price of $0.69. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Mar 01, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Hepion Pharmaceuticals's last stock rating was published by Cantor Fitzgerald on Mar 01, 2022. The company Initialise its HEPA rating from "null" to "Overweight".
Hepion Pharmaceuticals Financial Forecast
Hepion Pharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | $1.16B |
| High Forecast | - | - | - | $1.39B |
| Low Forecast | - | - | - | $928.38M |
| # Analysts | - | - | - | 15 |
| Surprise % | - | - | - | - |
Hepion Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HEPA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Hepion Pharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 15 |
| EBITDA | - | - | - | $-1.80M |
| Avg Forecast | - | - | - | $-2.23M |
| High Forecast | - | - | - | $-1.78M |
| Low Forecast | - | - | - | $-2.68M |
| Surprise % | - | - | - | 0.81% |
undefined analysts predict HEPA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Hepion Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Hepion Pharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 15 |
| Net Income | - | - | - | $-1.73M |
| Avg Forecast | $-13.24M | $-12.77M | $-21.51M | $-2.13M |
| High Forecast | $-13.24M | $-12.77M | $-21.51M | $-1.71M |
| Low Forecast | $-13.24M | $-12.77M | $-21.51M | $-2.56M |
| Surprise % | - | - | - | 0.81% |
Hepion Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HEPA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Hepion Pharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 15 |
| SG&A | - | - | - | $1.06M |
| Avg Forecast | - | - | - | $1.25M |
| High Forecast | - | - | - | $1.50M |
| Low Forecast | - | - | - | $997.58K |
| Surprise % | - | - | - | 0.85% |
Hepion Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to HEPA last annual SG&A of $1.06M (Sep 19).
Hepion Pharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 15 |
| EPS | - | - | - | $-0.50 |
| Avg Forecast | $-1.97 | $-1.90 | $-3.71 | $-0.75 |
| High Forecast | $-1.97 | $-1.90 | $-3.71 | $-0.60 |
| Low Forecast | $-1.97 | $-1.90 | $-3.71 | $-0.90 |
| Surprise % | - | - | - | 0.67% |
According to undefined Wall Street analysts, Hepion Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HEPA previous annual EPS of $NaN (undefined).